Compare CUE & PHUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CUE | PHUN |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 35.9M |
| IPO Year | 2017 | 2016 |
| Metric | CUE | PHUN |
|---|---|---|
| Price | $0.29 | $1.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.00 | ★ $7.25 |
| AVG Volume (30 Days) | ★ 366.6K | 203.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.14 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $9,287,000.00 | ★ $30,883,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.00 | $95.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 69.16 | 15.57 |
| 52 Week Low | $0.23 | $1.56 |
| 52 Week High | $1.21 | $3.88 |
| Indicator | CUE | PHUN |
|---|---|---|
| Relative Strength Index (RSI) | 39.68 | 49.31 |
| Support Level | $0.28 | $1.79 |
| Resistance Level | $0.36 | $2.04 |
| Average True Range (ATR) | 0.02 | 0.10 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 25.81 | 44.16 |
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.